Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

Treating diabetic retinopathy (DR ... Pre-clinical studies show that after treatment with NG004, the retinal vasculature of animals with retinopathy has a structure very similar to that of ...

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

Kodiak Sciences Inc. (Nasdaq: KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR").

Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an ...

However, while this treatment can keep abnormal ... need these every 25 to 60 days. Eye injections can help treat AMD and other conditions such as diabetic retinopathy and retinal vein occlusions.

Diabetic retinopathy (DR) is an important cause of avoidable blindness worldwide. Seventy percent of diabetes occur in low and lower-middle income countries. Clinical practice guidelines for the ...

According to Future Market Insight, the global diabetic retinopathy market is likely to reach USD 15.50 billion by 2033, registering a CAGR of 5.8%. This is a significant rise from the estimated value ...

“Susvimo presents a unique, convenient treatment alternative to routine eye injections for ... vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) and myopic choroidal ...

Diabetes can affect many parts of the body, including the eyes. Routine eye exams can help identify the early stages of eye ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and ...